十一因子抑制剂:抗凝固疗法的新视野
João Presume1,2, Jorge Ferreira1, Regina Ribeiras3
1Cardiology Department, Hospital de Santa Cruz, Centro Hospitalar Lisboa Ocidental, Av. Prof. Dr. Reinaldo Dos Santos, Carnaxide, 2790-134, Lisbon, Portugal.
Cardiology and therapy
|February 2, 2024
概括
新的XI/XIa因子抑制剂为抗凝固疗法提供了潜在的进步,解决了脆弱患者的残留风险. 研究探讨了它们在预防各种临床疾病中的血栓形成和栓塞方面的作用.
科学领域:
- 血液学 血液学 血液学
- 药理学 药理学是指药理学的学科.
- 心血管医学 心血管医学
背景情况:
- 抗凝治疗已经发展,直接口服抗凝剂提供了优势,但在管理血栓和出血风险方面仍然存在挑战.
- 易受伤害的患者群体需要改进抗凝策略,以减轻残留风险.
- XI/XIa因子抑制剂代表了抗凝固的新型治疗标.
研究的目的:
- 提供XI/XIa因子抑制剂作为新一类抗凝剂的综合性审查.
- 探索XI因子在凝血中的作用及其抑制的理由.
- 讨论XI/XIa因子抑制剂的潜在临床应用和正在进行的研究.
主要方法:
- 关于XI因子在凝血中的作用的现有文献的综述.
- 对基因证据和病理生理学数据的分析,支持XI因子抑制.
- 在开发中的各种XI/XIa因子抑制剂的探索.
- 目前正在进行的临床研究和最近发现的总结.
主要成果:
- 因子XI在凝血级联中起着重要作用,使其成为一个可行的治疗点.
- 目前正在研究多种类型的XI/XIa因子抑制剂,它们在各种适用性方面显示出有前途.
- 潜在的应用包括骨科手术中的血栓预防,心房动中的中风预防,以及与癌症相关的血栓的治疗.
结论:
- XI/XIa因子抑制剂在抗凝固药物领域是一个有前途的新领域,有可能在有效性和安全性之间提供更好的平衡.
- 进一步的研究和临床试验至关重要,以确定这些药物在不同患者群体中的最终作用和最佳使用.
- 这些抑制剂可以解决预防血栓事件的未满足需求,同时最大限度地减少出血并发症.
相关概念视频
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
698
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
698
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
525
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
525
01:20Extrinsic and Intrinsic Pathways of Hemostasis
7.7K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
7.7K
01:16Clot Retraction and Fibrinolysis
6.0K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
6.0K
01:13Therapeutic Index
4.3K
The therapeutic index of a drug is a key parameter in pharmacology that quantifies the relative safety of a drug by calculating the ratio between the dose that causes toxicity in half the population (50%) to the dose that proves to be effective for half the population (50%). It provides a spectrum of doses for a particular drug ranging from effective to potentially toxic. To illustrate, consider an anticoagulant agent like warfarin. It possesses a narrow window within its therapeutic index to...
4.3K